30507-21-2

Basic information

• Product Name: 2-[2-(4-methoxyphenyl)ethenyl]quinazolin-4(1H)-one
• CAS NO: 30507-21-2
• Molecular Formula: C₁₇H₁₄N₂O₂
• Molecular Weight: 278.3053
• Mol File: 30507-21-2.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 481.6°C at 760 mmHg
• Flash Point: 245.1°C
• Density: 1.19g/cm³
• Vapor Pressure: 1.96E-09mmHg at 25°C
• Refractive Index: 1.615
• CAS DataBase Reference: 2-[2-(4-methoxyphenyl)ethenyl]quinazolin-4(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[2-(4-methoxyphenyl)ethenyl]quinazolin-4(1H)-one(30507-21-2)
• EPA Substance Registry System: 2-[2-(4-methoxyphenyl)ethenyl]quinazolin-4(1H)-one(30507-21-2)

Safety Data

• Hazardous Substances Data: 30507-21-2(Hazardous Substances Data)

Usage

Chemical structure

2-[2-(4-methoxyphenyl)ethenyl]quinazolin-4(1H)-one is a chemical compound that contains a quinazolinone structure, a 4-methoxyphenyl group, and a vinyl group.

Physical properties

It is a yellow crystalline solid.

Pharmaceutical research

The compound is commonly used in pharmaceutical research due to its potential applications in drug development.

Antioxidant and antitumor properties

The compound has been studied for its potential antioxidant and antitumor properties and has shown promise in inhibiting cancer cell growth.

Antimicrobial research

It has been investigated for its potential as an antimicrobial agent and has exhibited inhibitory effects against certain microorganisms.

Upstream product

• 1769-24-0 2-methyl-4-quinazolone 
• 123-11-5 4-methoxy-benzaldehyde 
• 118-48-9 isatoic anhydride 
• 78-39-7 Triethyl orthoacetate 
• 24680-50-0 4-methoxy-trans-cinnamaldehyde 
• 28144-70-9 anthranilic acid amide 
• 50324-44-2 2-(2-hydroxy-2-(4-methoxyphenyl)ethyl)quinazolin-4(3H)-one 

Downstream Products

• 63660-82-2 2-<2-(4-methoxyphenyl)ethyl>quinazolin-4(3H)-one 
• 856093-31-7 4-chloro-2-(4-methoxy-phenethyl)-quinazoline 
• 1207435-87-7 4-chloro-2-((E)-2-(4-methoxy-phenyl)-vinyl)-quinazoline 

Relevant articles and documents

Novel benzenesulfonate scaffolds with a high anticancer activity and g2/m cell cycle arrest

Sulfonates, unlike their derivatives, sulphonamides, have rarely been investigated for their anticancer activity. Unlike the well-known sulphonamides, esters are mainly used as conve-nient intermediates in a synthesis. Here, we present the first in-depth

Synthesis and in vitro Leishmania promastigote growth inhibition efficacy of novel 4(3H)-quinazolinone derivatives

Molecular hybridization is an increasingly important strategy in rational drug design and development. A series of novel quinazolinone-triazole hybrids have been synthesized and their antileishmanial activity investigated. Derivatives (E)-3-(prop-2-yn-1-yl)-2-styrylquinazolin-4(3H)-one, and (E)-3-{[1-(4-bromobenzyl)-1H-1,2,3-triazol-4-yl]methyl}-2-styrylquinazolin-4(3H)-one were observed to moderately inhibit the growth of promastigotes. An overall lack of significant antileishmanial activity may be attributable to the poor aqueous solubility of the derivatives. Future research endeavors will focus on potential remediation by investigating the anchoring of hydrophilic moieties to the quinazolinone scaffold.

Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases

Aberrant activation of FMS-like tyrosine receptor kinase 3 (FLT3) is implicated in the pathogenesis of acute myeloid leukemia (AML) in 20–30% of patients. In this study we identified a highly selective (phenylethenyl)quinazoline compound family as novel potent inhibitors of the FLT3-ITD and FLT3-D835Y kinases. Their prominent effects were confirmed by biochemical and cellular proliferation assays followed by mice xenograft studies. Our modelling experiments and the chemical structures of the compounds predict the possibility of covalent inhibition. The most effective compounds triggered apoptosis in FLT3-ITD AML cells but had either weak or no effect in FLT3-independent leukemic and non-leukemic cell lines. Our results strongly suggest that our compounds may become therapeutics in relapsing and refractory AML disease harboring various ITD and tyrosine kinase domain mutations, by their ability to overcome drug resistance.